# r.hu-Erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/r-hu-erythropoietin-epo-treatment-of-pre-esrd-patients-slows-the-rate-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Mihály Tapolyai,Satoshi Kadomatsu,Manuel Perera-Chong |
| Citations | 23 |
| DOI | 10.1186/1471-2369-4-3 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmcnephrol.biomedcentral.com/track/pdf/10.1186/1471-2369-4-3 |
| OpenAlex ID | https://openalex.org/W1489657210 |
| PMID | 12809563 |
| Type | article |
| Year | 2003 |

## Paper authors

- [Mihály Tapolyai](https://scholariq.org/researchers/mihaly-tapolyai/)

## Paper journal

- [BMC Nephrology](https://scholariq.org/journals/bmc-nephrology/)

## Paper primary topic

- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)

## Paper topics

- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Potassium and Related Disorders](https://scholariq.org/topics/potassium-and-related-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.